Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Moodys
AstraZeneca
Baxter
Mallinckrodt
Harvard Business School

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Lucitanib

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Lucitanib: Sponsors, patents, clinical trial progress

Lucitanib is an investigational drug.

There have been 7 clinical trials for Lucitanib. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2013.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, and Triple Negative Breast Neoplasms. The leading clinical trial sponsors are Clovis Oncology, Inc., Servier, and Breast International Group.

There are eleven US patents protecting this investigational drug and ninety-five international patents.

Recent Clinical Trials for Lucitanib
TitleSponsorPhase
A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid TumorBristol-Myers SquibbPhase 1/Phase 2
A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid TumorClovis Oncology, Inc.Phase 1/Phase 2
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR)Immunomedics, Inc.Phase 1/Phase 2

See all Lucitanib clinical trials

Clinical Trial Summary for Lucitanib

Top disease conditions for Lucitanib
Top clinical trial sponsors for Lucitanib

See all Lucitanib clinical trials

US Patents for Lucitanib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Lucitanib   Start Trial Human anti-VEGFR-2/KDR antibodies KADMON CORPORATION, LLC (New York, NY)   Start Trial
Lucitanib   Start Trial Rho kinase inhibitors KADMON CORPORATION, LLC (New York, NY)   Start Trial
Lucitanib   Start Trial Rho kinase inhibitors Kadmon Corporation, LLC (New York, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Medtronic
Merck
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.